ArticleScientific reports2017
Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 85 citations in OpenAlex.
- The Diagnostic Accuracy of the Second Revision of the European Academy of Neurology/Peripheral Nerve Society Guideline for Diagnosing Chronic Inflammatory Demyelinating Polyradiculoneuropathy.European journal of neurology · 2026Article
- Neurofascin Antibodies in a Large Cohort of Inflammatory Neuropathies from India.Annals of Indian Academy of Neurology · 2026Article
- Clinical utility of human leukocyte antigen genotyping and immunoglobulin G4 autoantibody testing in autoimmune neurological diseases: A focused minireview.World journal of biological chemistry · 2026Review
- Case Report: Influenza B-triggered CIDP revealing PMP22-related Dejerine-Sottas-like neuropathy in a child-biphasic cytokine dynamics and response to immunotherapy.Frontiers in medicine · 2026Article
- Microbiota and mycobiota in chronic inflammatory demyelinating polyneuropathy: clinical and pathophysiological correlations.Frontiers in molecular neuroscience · 2026Article
- Efficacy, Safety, and Tolerability of Subcutaneous Efgartigimod PH20 in Chinese Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Prespecified Subpopulation Analysis of the Multicentre, Randomised-Withdrawal, Double-Blind, Placebo-Controlled, Phase II ADHERE Trial.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Case report: Unilateral optic atrophy and intracranial hypertension in anti-NF155 nodopathy: a case managed with sequential efgartigimod and rituximab.Frontiers in immunology · 2026Article
- The changing landscape of primary autoimmune neuropathies.Nature reviews. Neurology · 2025Review
- Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Immune-mediated insights into clinical and specific autoantibodies in acute and chronic immune-mediated nodo-paranodopathies.Arquivos de neuro-psiquiatria · 2025Review
- Genetic and metabolic inflammation signatures in chronic inflammatory demyelinating polyneuropathy: the role ofFrontiers in molecular neuroscience · 2025Article
- Targeting the neonatal Fc receptor (FcRn) is not beneficial in an animal model of chronic neuritis.Immunologic research · 2024Article
- Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort.Journal of neurology · 2024Article
- Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- A rare presentation of acute-onset chronic inflammatory demyelinating polyneuropathy with the detection of anti-GM3 and anti-sulfatides antibodies: a case report.Frontiers in immunology · 2024Article
- Challenges in the Early Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Adults: Current Perspectives.Therapeutics and clinical risk management · 2024Review
- Exploring the depths of IgG4: insights into autoimmunity and novel treatments.Frontiers in immunology · 2024Review
- Peptides From the Variable Domain of Immunoglobulin G as Biomarkers in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Autonomic nervous system involvement in chronic inflammatory demyelinating polyradiculoneuropathy: a literature review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Review
- Altered plasma membrane abundance of the sulfatide-binding protein NF155 links glycosphingolipid imbalances to demyelination.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a heterogeneous disease in which diverse autoantibodies have been described but systematic screening has never been performed. Detection of CIDP-specific antibodies may be clinically useful. We developed a screening protocol to uncover novel reactivities in CIDP. Sixty-five CIDP patients and 28 controls were included in our study. Three patients (4.6%) had antibodies against neurofascin 155, four (6.2%) against contactin-1 and one (1.5%) against the contactin-1/contactin-associated protein-1 complex. Eleven (18.6%) patients showed anti-ganglioside antibodies, and one (1.6%) antibodies against peripheral myelin protein 2. No antibodies against myelin protein zero, contactin-2/contactin-associated protein-2 complex, neuronal cell adhesion molecule, gliomedin or the voltage-gated sodium channel were detected. In IgG experiments, three patients (5.3%) showed a weak reactivity against motor neurons; 14 (24.6%) reacted against DRG neurons, four of them strongly (7.0%), and seven (12.3%) reacted against Schwann cells, three of them strongly (5.3%). In IgM experiments, six patients (10.7%) reacted against DRG neurons, while three (5.4%) reacted against Schwann cells. However, results were not statistically significant when compared to controls. Immunoprecipitation experiments identified CD9 and L1CAM as potential antigens, but reactivity could not be confirmed with cell-based assays. In summary, we describe a diverse autoantibody repertoire in CIDP patients, reinforcing the hypothesis of CIDP's pathophysiological heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.